Hemodialysis for acute kidney injury
Ask the expert
The report presents a summary of reimbursement situation for use of hemodialysis as treatment for acute kidney injury. The analysis will cover adult patients only.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of equipment of hemodialysis for acute kidney injury:
- Allmed Group (POLYPURE, HF)
- Asahi Kasei Medical (MDS-101, APS, Rexeed, ViE, KF-201, Cureflo)
- B. Braun (OMNI, Diapact CRRT, OMNIfilter, Haemoselect, Diacap, Dialog iQ, Xevonta, Diacap Pro)
- Baxter (Theranova, Prismaflex, Prismax, Phoenix X36, Polyflux 6H, Revaclear, Artis Physio)
- Bellco/Medtronic (SIMPLY BEYOND, AMPLYA, CARPEDIEM)
- Biolight Meditech (D-30, DTB-100F, DTB-100)
- CR Bard/ BD (Decathlon, Equistream, Glidepath, Hemosplit, Hickman, Reliance, Soft-cell, Power-trialysis, DuoGlide, Brevia, Niagara)
- Dialife Group (Diadvance)
- Informed (HF440)
- Farmasol (Dialyzer, Catridge)
- Kawasumi Laboratories (Dialyzers)
- Fresenius (multiFiltratePRO, multiFiltrate)
- Landwind Medical (AISO-3038, JHM-2028A, JHM-2028M, JH-4048, JH-5058)
- Medivators/Cantel
- Nikkiso (Aquarius, DBB-EXA, DBB-07, DBB-06, DBB-27, FDX, FDY)
- Nipro Medical (Surdial-X, Surdial – 55Plus, Elisio, Sureflux, Solacea)
- Medica (ACUSmart, Smartflux)
- Serumwerk Bernburg (Dialyzers, cartridges)
- SWS Medical (SWS-6000, SWS-4000, SWS-5000)
- Toray Medical (TQS-88, TR-8000)
- Outset Medical (Tablo)
Table of content is not available at the moment. Report is still ongoing.
27
Feb 2023
In January and February 2023, Ordering Forum for the “New Methods” framework invited interested parties regarding several technologies proposed for evaluation within the framework. The technologies concern arteriovenous fistula for hemodialysis, deep brain stimulation, epidural spinal cord stimulation, and digital chest drain. Ordering Forum will decide whether the technology undergoes evaluation at the national level.
Read more03
Feb 2023
On January 30, 2023, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2022. The medical technologies belonging to the cardiovascular, eHealth, gastrointestinal, neuromodulation, neurovascular, peripheral vascular, orthopedic, and other technology groups obtained positive status 1.
Read more12
Jan 2023
In December 2022, the National Institute for Health and Care Excellence (NICE) published one new Medical Technologies Guidance (Memokath 051 Ureter stent for ureteric obstruction) and one MedTech Innovation Briefing (PromarkerD). Also, two new clinical guidelines were published, and one was updated.
Read more19
Dec 2022
On December 1, 2022, the Swiss Federal Office of Public Health published the changes that will occur to the Services Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The updates will enter into force on January 1, 2023, and they relate to the list of explicitly evaluated services (Annex 1 of KLV/OPre), outpatient-before-hospital services (Annex 1a), List of Tools and Appliances(Annex 2), and List of Analyses (Annex 3).
Read more08
Dec 2022
The French National Authority for Health released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in November 2022. Twenty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, neurovascular and neuromodulation, endocrine, ENT, endoscopic and dermatological devices, as well as devices for men’s health and medical aids.
Read more